Dimercaptosuccinic Acid: From Chelation Therapy to Advanced Medical Applications
27 Aug 2026 • by Natalie Aster
Dimercaptosuccinic acid, widely known as DMSA or succimer, occupies a specialized but strategically important position in the pharmaceutical and diagnostic chemicals market. It is not a mass-volume commodity chemical. Its value is driven by high-purity medical use, chelation therapy, pediatric toxicology, nuclear medicine, and growing awareness of heavy metal exposure as a world’s public health issue.
The commercial relevance of DMSA begins with its established role as an orally active chelating agent. In the United States, CHEMET® succimer capsules are indicated for treating lead poisoning in pediatric patients aged one year and older with blood lead levels above 45 mcg/dL, and the label identifies succimer chemically as meso-2,3-dimercaptosuccinic acid.
Dimercaptosuccinic Acid Market Size & Growth Outlook
Published market estimates vary because some reports measure DMSA active pharmaceutical ingredient, some track succimer capsules, and others include broader specialty chemical or diagnostic uses. Even with that variation, the direction is clear: the DMSA market is expected to expand as healthcare systems strengthen toxicology response, pediatric lead screening, nuclear medicine imaging, and access to specialty chelation products.
A 2025 market estimates place the global dimercaptosuccinic acid market at around USD 274 million in 2024, with a projected rise to USD 513 million by 2031, while another forecast estimates the market at USD 300 million in 2024 and USD 500 million by 2035.
Lead Exposure Keeps Chelation Therapy Clinically Relevant
The DMSA market is closely connected to lead exposure, especially in children. Lead remains a global health burden despite decades of regulation in paint, fuel, water systems, consumer products, industrial processes, batteries, and informal recycling. WHO states that there is no known safe blood lead concentration, and its 2026 fact sheet reports that more than 3.5 million deaths across the globe were attributed to lead exposure in 2023, mainly through cardiovascular effects.
Childhood exposure remains a major demand driver for clinical testing, public health intervention, and specialist treatment. UNICEF and Pure Earth reported that around one in three children worldwide, up to 800 million children, had blood lead levels at or above 5 µg/dL. The CDC currently uses a blood lead reference value of 3.5 µg/dL to identify children with higher blood lead levels than most U.S. children.
DMSA is not a general wellness ingredient; it belongs in supervised medical use. The FDA has warned consumers against unapproved chelation products marketed as supplements, noting that FDA-approved chelation therapies require prescriptions because they must be used under healthcare supervision.
From Chelation Therapy to Renal Imaging Applications
Beyond oral chelation, DMSA has an important diagnostic role in nuclear medicine. Technetium-99m DMSA renal imaging is used to evaluate renal cortical function, kidney morphology, pyelonephritis-related changes, and renal scarring. A 2024 review in the Journal of Nuclear Medicine Technology described 99mTc-DMSA renal imaging as a well-established technique and confirmed ongoing clinical need for the agent.
Pediatric kidney imaging adds another layer of market relevance. NICE guidance recommends using a DMSA scan 4 to 6 months after acute infection to detect renal parenchymal defects in babies and children where indicated. This makes DMSA part of a broader medical ecosystem that includes radiopharmaceutical kits, hospital nuclear medicine departments, pediatric nephrology, and diagnostic imaging workflows.
Future Outlook for the Dimercaptosuccinic Acid Market
The future of the dimercaptosuccinic acid market will be shaped by three linked forces: public health pressure from heavy metal exposure, pharmaceutical-grade supply requirements, and advanced diagnostic applications. Growth will not come from mass consumption; it will come from reliability, regulatory compliance, purity, clinical access, and specialized medical demand.
As governments expand lead monitoring, hospitals improve toxicology response, and nuclear medicine continues to refine pediatric renal imaging, DMSA is likely to remain a high-value niche chemical with durable medical importance. The strongest opportunities will be in prescription succimer formulations, high-purity API production, radiopharmaceutical applications, and healthcare systems building stronger capacity to diagnose and treat heavy metal exposure.
Related Reports:
- DIMERCAPTOSUCCINIC ACID (CAS 2418-14-6) Market Research Report 2026
- 2,3-Dimercaptosuccinic acid (DMSA) (CAS 304-55-2) Market Research Report 2026
- Succimer (CAS 304-55-2) Market Research Report 2026
- 2026-2031 Global Dimercaptosuccinic Acid Outlook Market Size, Share & Trends Analysis Report By Player, Type, Application and Region
- Global Dimercaptosuccinic Acid Capsule Market Growth 2025-2031
- Global Dimercaptosuccinic Acid Market Research Report 2026(Status and Outlook)
- Global Heavy Metal Detoxification Drug Market Research Report 2026(Status and Outlook)
Market Publishers boasts a rich collection of insightful research studies covering the chemicals and petrochemicals market, find it in the Chemicals & Petrochemicals Market Reports Catalogue.
CONTACTS
The Market Publishers, Ltd.
Natalie Aster
Tel: +357 96 030 922
[email protected]
MarketPublishers.com
Analytics & News
